Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial.

Abstract

A total of 112 patients with recurrent lower urinary tract infection (UTI) completed the 6-month period of the trial. Patients were treated for 3 months, under double-blind conditions, with one capsule daily of either Uro-Vaxom (UV) or placebo, together with an antibiotic or chemotherapeutic agent when necessary, and observed for a further 3 months. During the 6 months of the trial a significant decrease in the number of recurrences (p < 0.0005) was noted in the UV group as compared to the placebo group. A total of 67.2% of the patients had no recurrences (p < 0.0005). The incidence of bacteriuria (germs > or = 10(5)/ml), dysuria and leukocyturia was significantly reduced. UV was well tolerated, no side effects were recorded during the trial. The drug is a useful adjuvant for the management of UTIs and for the prevention of recurrences.

• Authors: P Magasi, J Pánovics, A Illés, M Nagy
• Journal: European urology (Eur Urol) Vol. 26 Issue 2 Pg. 137-40 ( 1994) ISSN: 0302-2838 [Print] Switzerland
• PMID: 7957468 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Adjuvants, Immunologic
• Anti-Infective Agents, Urinary

Topics

• Adjuvants, Immunologic (therapeutic use)
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anti-Infective Agents, Urinary (therapeutic use)
• Double-Blind Method
• Escherichia coli
• Female
• Humans
• Male
• Middle Aged
• Recurrence
• Time Factors
• Urinary Tract Infections (drug therapy)